Prof John Masters

Photo

Personal Profile

Name: John Masters Email: j.masters@ucl.ac.uk
Title: Prof Tel: 0044 20 7679 9543
Department: Research Department of Urology Fax:
Position: Professor of Experimental Pathology Address: Prostate Cancer Research Centre, 67 Riding House Street, , London, W1W 7EJ
Research Domain: Cancer, Neuroscience, Personalised Medicine Web Page:  

Profile

Research Description


Research Activities

Prostate cancer

Education Description

UCL Collaborators

Prof Kerry Chester; Mr Hashim Ahmed; Prof Mark Emberton

External Collaborators

Publications

    2014

    • Symes AJ, Eilertsen M, Millar M, Nariculam J, Freeman A, Notara M, Feneley MR, Patel HR, Masters JR, Ahmed A (2014). Correction: Quantitative Analysis of BTF3, HINT1, NDRG1 and ODC1 Protein Over-Expression in Human Prostate Cancer Tissue.. PLoS One, 9(1), - . doi:10.1371/annotation/80c6bb6d-657b-46be-ba77-3de5d528c89e
    • Beaver CM, Ahmed A, Masters JR (2014). Clonogenicity: holoclones and meroclones contain stem cells.. PLoS One, 9(2), e89834 - . doi:10.1371/journal.pone.0089834

    2013

    • Capes-Davis A, Alston-Roberts C, Kerrigan L, Reid YA, Barrett T, Burnett EC, Cooper JR, Dirks WG, Macleod RAF, Drexler HG, Freshney RI, Healy L, Kohara A, Korch C, Masters JRW, Nakamura Y, Nims RW, Storts DR (2013). Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line. Genes Chromosomes and Cancer, 52(10), 986 - 988. doi:10.1002/gcc.22094
    • Capes-Davis A, Reid YA, Sykes G, Alston-Roberts C, Kerrigan L, Kline MC, Storts DR, Strauss E, Dirks WG, Drexler HG, MacLeod RAF, Kohara A, Nakamura Y, Elmore E, Nims RW, Barallon R, Thomson J, Los GV, Nardone RM, Price PJ, Steuer A, Masters JRW (2013). Match criteria for human cell line authentication: Where do we draw the line?. International Journal of Cancer, 132(11), 2510 - 2519. doi:10.1002/ijc.27931
    • Williamson MP (2013). Function of mutant and wild-type plexinB1 in prostate cancer cells. The Prostate, , - .
    • Capes-Davis A, Alston-Roberts C, Kerrigan L, Reid YA, Barrett T, Burnett EC, Cooper JR, Dirks WG, Macleod RA, Drexler HG, Freshney RI, Healy L, Kohara A, Korch C, Masters JR, Nakamura Y, Nims RW, Storts DR (2013). Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line.. Genes Chromosomes Cancer, , - . doi:10.1002/gcc.22094
    • Damola A, Legendre A, Ball S, Masters JR, Williamson M (2013). Function of mutant and wild-type plexinb1 in prostate cancer cells. Prostate, 73(12), 1326 - 1335. doi:10.1002/pros.22678
    • Symes AJ, Eilertsen M, Millar M, Nariculam J, Freeman A, Notara M, Feneley MR, Patel HR, Masters JR, Ahmed A (2013). Quantitative Analysis of BTF3, HINT1, NDRG1 and ODC1 Protein Over-Expression in Human Prostate Cancer Tissue.. PLoS One, 8(12), e84295 - . doi:10.1371/journal.pone.0084295
    • Legendre A, Masters JRW, Williamson M (2013). Plexin B1 trafficking in prostate cancer. doi:10.1158/1538-7445.AM2013-4077
    • Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A, Nakamura Y, Elmore E, Nims RW, Alston-Roberts C, Barallon R, Los GV, Nardone RM, Price PJ, Steuer A, Thomson J, Masters JR, Kerrigan L (2013). Match criteria for human cell line authentication: where do we draw the line?. Int J Cancer, 132(11), 2510 - 2519. doi:10.1002/ijc.27931

    2012

    • Legendre A, Williamson M, Masters JR (2012). Plexin B1 Trafficking in Prostate Cancer.
    • Masters JR (2012). Cell-line authentication: End the scandal of false cell lines.. Nature, 492(7428), 186 - . doi:10.1038/492186a
    • Zhou C, Wong OG, Masters JR, Williamson M (2012). Effect of cancer-associated mutations in the PlexinB1 gene.. Mol Cancer, 11, 11 - . doi:10.1186/1476-4598-11-11
    • Yamamoto H, Masters JR, Ahmed A, Dasgupta P, Popert R, Chandra A, Freeman A (2012). CD49f Is an Efficient Marker of Monolayer- and Spheroid Colony-Forming Cells of the Benign and Malignant Human Prostate. PLoS ONE, 7(10), - . doi:10.1371/journal.pone.0046979
    • Barron N, Keenan J, Gammell P, Martinez VG, Freeman A, Masters JR, Clynes M (2012). Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.. Prostate, 72(11), 1193 - 1199. doi:10.1002/pros.22469

    2011

    • Blanc V, Nariculam J, Munson P, Freeman A, Masters JRW, Williamson M (2011). A role for Class 3 semaphorins in prostate cancer. Prostate, 71, 649 - 658.
    • Masters JR (2011). Prostate cancer proteomics.. OMICS, 15(3), 169 - 171. doi:10.1089/omi.2010.0083

    2010

    • Barallon R, Bauer SR, Butler J, Capes-Davis A, Dirks WG, Elmore E, Furtado M, Kline MC, Kohara A, Los GV, MacLeod RAF, Masters JRW, Nardone M, Nardone RM, Nims RW, Price PJ, Reid YA, Shewale J, Sykes G, Steuer AF, Storts DR, Thomson J, Taraporewala Z, Alston-Roberts C, Kerrigan L (2010). Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. IN VITRO CELL DEV-AN, 46(9), 727 - 732. doi:10.1007/s11626-010-9333-z
    • Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR, Freshney RI (2010). Check your cultures! A list of cross-contaminated or misidentified cell lines.. Int J Cancer, 127(1), 1 - 8. doi:10.1002/ijc.25242
    • Wells CM, Whale AD, Parsons M, Masters JRW, Jones GE (2010). PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J CELL SCI, 123(10), 1663 - 1673. doi:10.1242/jcs.055707
    • Masters JRW (2010). Cell line misidentification: the beginning of the end. NAT REV CANCER, 10(6), 441 - 448. doi:10.1038/nrc2852
    • Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, Thrasivoulou C, Masters JR, Ahmed A (2010). A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer.. PLoS One, 5(5), e10456 - . doi:10.1371/journal.pone.0010456
    • Young L, Sung J, Stacey G, Masters JR (2010). Detection of Mycoplasma in cell cultures.. Nat Protoc, 5(5), 929 - 934. doi:10.1038/nprot.2010.43

    2009

    • Nariculam J, Freeman A, Munson P, Bott SJ, Cable N, Brookman-Amissah N, Williamson M, Feneley MR, Masters JRW (2009). Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the experession of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian Journal of Andrology, 11, 109 - 118.
    • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters JRW, Parmar MKB (2009). Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm multi-stage randomised controlled trial. BJUI, 103, 464 - 469.
    • Price KL, Hulton SA, van't Hoff WG, Masters JR, Rumsby G (2009). Primary cultures of renal proximal tubule cells derived from individuals with primary hyperoxaluria.. Urol Res, 37(3), 127 - 132. doi:10.1007/s00240-009-0185-5
    • MASTERS J, PALSSON B (2009). Human cell culture volume 7: Human adult stem cells.

    2008

    • Ahmed T, Shea K, Masters JRW, Jones GE, Wells CM (2008). A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cellular Signalling, 20, 1320 - 1328.
    • Masters JRW, Stacey G (2008). Cryopreservation and banking of mammalian cell lines. Nature Protocols, 3, 1981 - 1989.
    • Nitkunan T, Wong OGW, Zhou C, Nariculam J, Munson P, Constantinou J, Freemen A, Masters JR, Williamson M (2008). Plexin-B1 mutations and prostate cancer.
    • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MKB (2008). STAMPEDE: Systemic therapy for advancing or metastaic prostate cancer - a multi-arm multi-stage randomised clinical trial. Clinical Oncology, 20, 577 - 581.
    • Hastie C, Masters JR, Moss SE, Naaby-Hansen S (2008). Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. Journal of Biological Chemistry, 283, 12595 - 12603.
    • Köberle B, Roginskaya V, Zima KS, Masters JRW, Wood RD (2008). Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation.. Molecular Carcinogenesis, 47, 580 - 586.

    2007

    • MASTERS J, PALSSON B, THOMSON J (2007). Human cell culture volume 6: Human embryonic stem cells.
    • Masters JR, Stacey GN (2007). Changing medium and passaging cell lines. Nature protocols, 2, 2276 - 2284.
    • Price KL, Woolf AS, Jina N, Hubank M, Masters JM, Rumsby G (2007). The effect of oxalate exposure on the cell biology of human renal proximal tubule cells, in Proceedings of the 8th International Primary Hyperoxaluria Workshop, UCL-Institute of Child Health, 29-30 June 2007, C. J. Danpure & G. Rumsby, eds., Springer Berlin, Heidelberg,.
    • Price KL, Hulton S-A, Woolf AS, Masters JM, Rumsby G (2007). Primary cultures of renal proximal tubule cells derived from individuals with primary hyperoxaluria, in Proceedings of the 8th International Primary Hyperoxaluria Workshop, UCL-Institute of Child Health, 29-30 June 2007, C. J. Danpure & G. Rumsby, eds., Springer Berlin, Heidelberg.
    • Brookman-Amissah N, Nariculam J, Freeman A, Williamson M, KirbyR S M, J R F, M R (2007). Allelic imbalance at 13q14.2-q14.3 in localized prostate cancer is associated with early biochemical relapse. Cancer Genetics and Cytogenetics, 179, 118 - 126.
    • Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O'Hare MJ, Masters JR, Hudson DL (2007). A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation. DIFFERENTIATION, 75(1), 35 - 48. doi:10.1111/j.1432-0436.2006.00113.x
    • Masters JR (2007). Clinical applications of expression profiling and proteomics in prostate cancer. ANTICANCER RES, 27(3A), 1371 - 1371.
    • Price KL, Hulton SA, Masters JR, Rumsby G (2007). Primary cultures of renal proximal tubule cells derived from individuals with primary hyperoxaluria.
    • Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJF, Ahmed A, Masters JR (2007). Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene, 26(45), 6560 - 6565. doi:10.1038/sj.onc.1210472
    • Wong OG, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown RSD, Bott SRJ, Nariculam J, Box G, Munson P, Constantinou J, Feneley MR, Klocker H, Eccles SA, Negishi M, Freeman A, Masters JR, Williamson M (2007). Plexin-B1 mutations in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(48), 19040 - 19045. doi:10.1073/pnas.0702544104
    • Price KL, Woolf AS, Jina N, Hubank M, Masters JR, Rumsby G (2007). The effect of oxalate exposure on the cell biology of human renal proximal tubule cells.

    2006

    • Bott SR, Masters JRW, Parkinson MC, Kirby RS, Feneley M, Hooper J (2006). M. Allelic imbalance and biochemical outcome after radical prostatectomy. Cancer and Prostatic Diseases, (9), 160 - 168.
    • McGurk CJ, Cummings M, Koberle B, Hartley JA, Oliver RT, Masters JR (2006). Regulation of DNA repair gene expression in human cancer cell lines. JOURNAL OF CELLULAR BIOCHEMISTRY, 97(5), 1121 - 1136.
    • Cummings M, Higginbottom K, McGurk CJ, Wong OG, Köberle B, Oliver RT, Masters JR (2006). XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.. Biochem Pharmacol, 72(2), 166 - 175. doi:10.1016/j.bcp.2006.04.025
    • Bott SRJ, Masters JRW, Parkinson MC, Kirby R S F, M H, J W, M (2006). Allelic imbalance and biochemical outcome after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 9(2), 160 - 168.

    2005

    • Laczko I, Hudson DL, Freeman A, Feneley MR, Masters JR (2005). Comparison of the zones of the human prostate with the seminal vesicle: Morphology, immunohistochemistry, and cell kinetics. The Prostate, 62(3), 260 - 266.
    • Hastie C, Saxton M, Akpan A, Cramer R, Masters JR, Naaby-Hansen S (2005). Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells.. Oncogene, 24(38), 5905 - 5913. doi:10.1038/sj.onc.1208747
    • Brookman-Amissah N, Duchesnes C, Williamson MP, Wang Q, Ahmed A, Feneley MR, Mackay A, Freeman A, Fenwick K, Iravani M, Weber B, Ashworth A, Masters JR (2005). Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH. PROSTATE CANCER AND PROSTATIC DISEASES, 8(4), 335 - 343.
    • Birtle AJ, Freeman A, Masters JRW, Payne HA, Harland SJ (2005). Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < 10 ng/mL. BJU International, 96(3), 303 - 307.
    • Wells CM, Ahmed T, Masters JRW, Jones GE (2005). Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. CELL MOTILITY AND THE CYTOSKELETON, 62(3), 180 - 194.
    • AHMED A, BISSON I, FOLEY C, MASTERS J (2005). Prostate cancer stem cells. In KIRBY R, PARTIN A, FENELEY M, KELLOGG PARSONS J (Ed.), Prostate cancer: Surgical principles and practice (pp. - ). : Taylor and Francis.

    2004

    • Alam TN, O'Hare MJ, Laczko I, Freeman A, Al-Beidh F, Masters JRW, Hudson DL (2004). Differential expression of CD44 during human prostate epithelial cell differentiation. Journal of Histochemistry and Cytochemistry, 52, 1083 - 1090.
    • AHMED A, BISSON I, FOLEY C, MASTERS J (2004). Prostate stem cells. In (Ed.), Progress in stem cell research, volume 1 (pp. - ). : Nova Science.
    • Welsh C, Day R, McGurk C, Masters JRW, Woods RD, Koberle B (2004). Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. International Journal of Cancer, 110, 352 - 361.

    2003

    • Cummings M, McGurk C, Masters JRW (2003). Stability of the nucleotide excision repair proteins ERCC1 and XPA.
    • Masters JRW, Alam T, Foley CL, Laczko I, Hudson DL (2003). Stem cells and differentiation in human prostate cancer. In Bangma CH, Newling DWW (Ed.), Prostate cancer, benign prostatic hyperplasia, erectile dysfunction and basic research (pp. 145 - 154). : The Parthenon Publishing Group.
    • Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R, Naaby-Hansen S (2003). Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene, 23, 1693 - 1703.
    • COLVILLE C, MASTERS J, PARKINSON M (2003). The prostate and cancer: an introduction to normal morphology and histopathology for research scientists. In ABDEL P, LALANI E-N (Ed.), Prostate Cancer. Clinical scientific aspects - bridging the gap (pp. 111 - 140). : Imperial College Press.
    • Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ, BAUS Section of Oncology Cancer Registry (2003). Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.. Cancer, 98(11), 2362 - 2367. doi:10.1002/cncr.11821
    • Arya M, Tatoud R, McGurk C, O'Donoghue N, Klocker H, Williamson M, Masters JR (2003). The importance of the CXCL12 : CXCR4 chemokine ligand: Receptor interaction in prostate cancer metastasis.
    • Masters JRW, Williamson M (2003). Cancer associated plexinB1 mutations.
    • Masters JRW, Vani UD, Grigor KM, Griffiths GO, Crook A, Parmar MKB, Knowles MA (2003). Can p53 staining be used to identify patients with aggressive superficial bladder cancer?. The Journal of Pathology, 200, 74 - 81.
    • Masters JRW, Koberle B (2003). Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Cancer Reviews, 3, 517 - 525.
    • HUDSON D, MASTERS J (2003). Prostate epithelial stem cell isolation and culture. In RUSSELL P, JACKSON P, KINGSLEY E (Ed.), Methods in molecular medicine 81: Prostate cancer methods and protocols (pp. 59 - 67). : Humana Press Inc.,.
    • Cummings M, McGurk C, Masters JRW (2003). Rapid identification of antisense mRNA-expressing clones using strand-specific RT-PCR. Antisense and Nucleic Acid Drug Development, 13, 115 - 117.

    2002

    • Brown RSD, Dogan A, Ell PJ, Payne HA, Masters JRW, Harland SJ (2002). The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer. Prostate Cancer and Prostatic Diseases, 5(2), 144 - 151.
    • Brown RSD, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JMS, Masters JRW (2002). Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. The Journal of Pathology, 198(2), 237 - 244.
    • SOUTHGATE J, MASTERS J, TREJDOSIEWICZ L (2002). Culture of human urothelium. In FRESHNEY R, FRESHNEY M (Ed.), Culture of epithelial cells (pp. 381 - 399). : Wiley-Liss.
    • Masters JRW (2002). Hela cells 50 years on: the good, the bad and the ugly. Nature Reviews Cancer, 2, 315 - 319.
    • Masters JR (2002). False cell lines: The problem and a solution.. Cytotechnology, 39(2), 69 - 74. doi:10.1023/A:1022908930937

    2001

    • Masters JRW, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KL, Debenham PG (2001). Short tandem repeat profiling provides an international reference standard for human cell lines.. Proceedings of the National Academy of Sciences of the United States of America, 98(14), 8012 - 8017. doi:10.1073/pnas.1216198
    • (2001). Epithelial cell differentiation pathways in the human prostate: Identification of intermediate phenotypes by keratin expression. Journal of Histochemistry and Cytochemistry, 49(2), 271 - 278.
    • MASTERS J (2001). Human cell culture volume 5: Mesenchymal cells.
    • Wang X, Master JRW, Wong YC, Lo AKF, Tsao SW (2001). Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Anticancer Research, 21, 403 - 408.
    • Masters JRW (2001). Methods to improve the efficacy of intravesical mitomycin C: results of a randomized phase III trial. Journal of the National Cancer Institute, 93, 1574 - 1575.
    • Rossi MR, Masters JRW, Park S, Todd JH, Garrett SH, Sens MA, Somji S, Nath J, Sens DA (2001). The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environmental Health Perspectives, 109(8), 801 - 808.

    2000

    • MASTERS J (2000). Human cell culture volume 3: Leukemia and lymphoma cell lines.
    • MASTERS J, PALSSON B (2000). Human cell culture volume 2: Cancer cell lines part 2.
    • Masters JR, Lakhani SR (2000). How diagnosis with microarrays can help cancer patients.. Nature, 404(6781), 921 - .
    • Masters JRW, Twentyman P, Daley R, Davis J, Doyle A, Dyer S, Freshney I, Galpine A, Harrison M, Hurst H, Kelland L, Stacey G, Stratford I, Ward TH, UKCCCR (2000). UKCCCR guidelines for the use of cell lines in cancer research. BRIT J CANCER, 82(9), 1495 - 1509.
    • Masters JR (2000). Human cancer cell lines: fact and fantasy.. Nature Reviews Molecular Cell Biology, 1(3), 233 - 236.
    • FRY P, HUDSON D, O'HARE M, MASTERS J (2000). Comparison of marker protein expression in benign prostatic hyperplasia in vivo and in vitro. Br J Urol, 86, 504 - 513.
    • Stacey GN, Masters JRW, Hay RJ, Drexler HG, MacLeod BAF, Freshney RI (2000). Cell contamination leads to inaccurate data: we must take action now. Nature, 403, 356 - .
    • MASTERS J (2000). Cancer cell lines. Nature Reviews Molecular Cell Biology, 1, 233 - 236.
    • HUDSON D, O'HARE M, WATT F, MASTERS J (2000). Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest, 80, 1243 - 1250.
    • MASTERS J (2000). Animal cell culture.

    1999

    • Koberle B, Masters JRW, Hartley JA, Wood RD (1999). Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Current Biology, 9, 273 - 276.
    • Fry PM, Wu C, O'Hare MJ, Masters JR, Fry CH (1999). Functional and immunocytochemical characterisation of human prostate stromal cells.
    • MASTERS J, POPERT R, THOMPSON P, GIBSON D, COPTCOAT M, PARMAR M (1999). Comparison of two doses of epirubicin for intravesical chemotherapy of superficial bladder cancer. J Urol, 161, 1490 - 1493.
    • KNUECHEL R, MASTERS J (1999). Bladder Cancer. In MASTERS J, PALSSON B (Ed.), Human cell culture, volume 1, cancer cell lines part 1 (pp. 213 - 230). : .
    • O'Neill CF, Koberle B, Masters JR, Kelland LR (1999). Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.. British Journal of Cancer, 81(8), 1294 - 1303.
    • BAI X, MASTERS J, O'DONOGHUE E, KIRBY R, PAN L, YOUNG M, PARKINSON M (1999). Prognostic markers in clinically localised prostate cancer. Int J Oncol, 14, 785 - 791.
    • MASTERS J (1999). Human cell culture volume 4: Haematopoietic cells.
    • MASTERS J, PALSSON B (1999). Human cell culture volume 1: Cancer cell lines part 1.

    1998

    • McAdam SR, Knox RJ, Hartley JA, Masters JRW (1998). KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithio-ethyl] mitomycin C): DNA interactions and drug uptake following serum activation. Biochemical Pharmacology, 55(11), 1777 - 1783.
    • Sabbagh W, Masters JRW, Duffy PG, Herbage D, Brown RA (1998). In vitro assessment of a collagen sponge for engineering urothelial grafts. British Journal of Urology, 82, 888 - 894.
    • Wang X, Fox M, Povey S, Masters JR (1998). Mouse-human somatic cell hybrids: loss of mouse and human chromosomes.. Somatic Cell and Molecular Genetics, 24(3), 165 - 171.
    • Bai XZ, Parkinson MC, Pan L, Youngj M, Kirby R, O'Donoghue EPN, Masters JRW (1998). Prognostic markers for radical prostatectomy. British Journal of Urology, 81(SUPPL. 4), 12 - 12.

    1997

    • Masters JRW, Knox RJ, Hartley JA, Kelland LR, Hendriks H, Connors T (1997). KW-2149 (7-N-[2-[gamma-L glutamylamino]ethyldithioethyl]mitomycin C): a new mitomycin-C activated by serum. Biochemical Pharmacology, 53, 279 - 285.
    • Wang X, Hafezparast M, Masters JRW (1997). Complementation analysis of testis tumour cells. Cancer Genetics and Cytogenetics, 98, 56 - 62.
    • Koberle B, Grimaldi K, Sunters A, Hartley JA, Kelland LR, Masters JRW (1997). DNA repair capacity and cisplatin sensitivity of human testis tumour cells. International Journal of Cancer, 70, 551 - 555.

    1996

    • Smith CM, Masters JRW, Ballard SA, Worman N, Buettner R (1996). 5α-Reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. Journal of Clinical Endocrinology and Metabolism, 81(4), 1361 - 1366. doi:10.1210/jc.81.4.1361
    • Chresta CM, Masters JRW, Hickman JA (1996). Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. CANCER RES, 56(8), 1834 - 1841.
    • Masters JRW, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H (1996). Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways. EUR J CANCER, 32A(7), 1248 - 1253.
    • Davies SL, Popert R, Coptcoat M, Hickson ID, Masters JRW (1996). Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. INT J CANCER, 65(1), 63 - 66.
    • Wang XH, Hafezparast M, Masters JRW (1996). Genetic basis of drug sensitivity in human testis tumour cells. INT J CANCER, 65(4), 426 - 431.
    • Smith CM, Ballard SA, Worman N, Buettner R, Masters JRW (1996). 5 alpha-Reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J CLIN ENDOCR METAB, 81(4), 1361 - 1366.
    • Masters JRW, McDermott BJ, Harland S, Bibby MC, Loadman PM (1996). ThioTEPA pharmacokinetics during intravesical chemotherapy: The influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. CANCER CHEMOTH PHARM, 38(1), 59 - 64.
    • Richards EH, Hickey E, Weber L, Masters JRW (1996). Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. CANCER RES, 56(10), 2446 - 2451.
    • Richards EH, Begum TA, Masters JRW (1996). Thermotolerance and sensitivity of human cancer cells to cisplatin and doxorubicin. INT J ONCOL, 8(6), 1265 - 1271.
    • Masters JRW, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H (1996). Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways. European Journal of Cancer Part A, 32(7), 1248 - 1253. doi:10.1016/0959-8049(96)00033-0
    • Koberle B, Payne J, Grimaldi KA, Hartley JA, Masters JRW (1996). DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. BIOCHEM PHARMACOL, 52(11), 1729 - 1734.

    1995

    • Petzoldt JL, Leigh IM, Duffy PG, Sexton C, Masters JRW (1995). Immortalisation of human urothelial cells. UROL RES, 23(6), 377 - 380.
    • RICHARDS EH, HICKMAN JA, MASTERS JRW (1995). HEAT-SHOCK PROTEIN EXPRESSION IN TESTIS AND BLADDER-CANCER CELL-LINES EXHIBITING DIFFERENTIAL SENSITIVITY TO HEAT. BRIT J CANCER, 72(3), 620 - 626.
    • PERA MF, KOBERLE B, MASTERS JRW (1995). EXCEPTIONAL SENSITIVITY OF TESTICULAR GERM-CELL TUMOR-CELL LINES TO THE NEW ANTICANCER AGENT, TEMOZOLOMIDE. BRIT J CANCER, 71(5), 904 - 906.
    • POPERT RJM, MASTERS JRW, COPTCOAT M, ZUPI G (1995). RELATIVE CYTOTOXICITIES OF ADRIAMYCIN AND EPIRUBICIN IN COMBINATION WITH LONIDAMINE AGAINST HUMAN BLADDER-CANCER CELL-LINES. UROL RES, 22(6), 367 - 372.

    1994

    • Smith CM, Ballard SA, Wyllie MG, Masters JRW (1994). Comparison of testosterone metabolism in benign prostatic hyperplasia and human prostate cancer cell lines in vitro. Journal of Steroid Biochemistry and Molecular Biology, 50(3-4), 151 - 159. doi:10.1016/0960-0760(94)90022-1
    • LYNCH M, MASTERS J, PRYOR J, LINDON J, SPRAUL M, FOXALL P, NICHOLSON J (1994). Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J Pharm Biomed Analysis, 12, 5 - 19.
    • PETZOLDT JL, LEIGH IM, DUFFY PG, MASTERS JRW (1994). CULTURE AND CHARACTERIZATION OF HUMAN UROTHELIUM IN-VIVO AND IN-VITRO. UROL RES, 22(2), 67 - 74.
    • POPERT RJM, GOODALL J, COPTCOAT MJ, THOMPSON PM, PARMAR MKB, MASTERS JRW (1994). SUPERFICIAL BLADDER-CANCER - THE RESPONSE OF A MARKER TUMOR TO A SINGLE INTRAVESICAL INSTILLATION OF EPIRUBICIN. BRIT J UROL, 74(2), 195 - 199.

    1993

    • MASTERS JRW, PETZOLDT JL (1993). IN-VITRO STUDIES ON THE PATHOGENESIS OF BLADDER-CANCER.
    • BRITTEN RA, WARENIUS HM, MASTERS JRW, PEACOCK JH, BIOL CI (1993). THE DIFFERENTIAL INDUCTION OF COLLATERAL RESISTANCE TO 62.5-MEV (P-]BE+) NEUTRONS AND 4-MEV PHOTONS BY EXPOSURE TO CISPLATINUM. INT J RADIAT ONCOL, 26(5), 837 - 843.
    • Masters JR, Osborne EJ, Walker MC, Parris CN (1993). Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs.. Int J Cancer, 53(2), 340 - 346.
    • McLAUGHLIN K, COREN G, MASTERS J, BROWN R (1993). Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. Int. J. Cancer, 53, 662 - 666.
    • AYOUB F, ZAMAN M, THORNALLEY P, MASTERS J (1993). Glyoxalase activities in human tumour cell lines in vitro. Anticancer Res.,, 13, 151 - 156.

    1992

    • Fermor BF, Masters JRW, Wood CB, Miller J, Apostolov K, Habib NA (1992). Fatty acid composition of normal and malignant cells and cytotoxicity of stearic, oleic and sterculic acids in vitro. European Journal of Cancer Part A: General Topics, 28(6-7), 1143 - 1147.
    • LERUPPERT K, MASTERS JRW, KNUECHEL R, SEEGERS S, TAINSKY MA, HOFSTAEDTER F, BUETTNER R (1992). THE EFFECT OF RETINOIC ACID ON CHEMOSENSITIVITY OF PA-1 HUMAN TERATOCARCINOMA CELLS AND ITS MODULATION BY AN ACTIVATED N-RAS ONCOGENE. INT J CANCER, 51(4), 646 - 651.
    • FERMOR BF, MASTERS JRW, WOOD CB, MILLER J, APOSTOLOV K, HABIB NA (1992). FATTY-ACID COMPOSITION OF NORMAL AND MALIGNANT-CELLS AND CYTOTOXICITY OF STEARIC, OLEIC AND STERCULIC ACIDS INVITRO. EUR J CANCER, 28A(6-7), 1143 - 1147.
    • Walker MC, Masters JR, Margison GP (1992). O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines.. Br J Cancer, 66(5), 840 - 843.
    • MASTERS JRW, CAMPLEJOHN RS, PARKINSON MC, WOODHOUSE CRJ, OREILLY SM (1992). DOES DNA FLOW-CYTOMETRY GIVE USEFUL PROGNOSTIC INFORMATION IN RENAL PARENCHYMAL ADENOCARCINOMA. BRIT J UROL, 70(4), 364 - 369.
    • MASTERS JRW, JENKINS WEA, SHOEMAKER RH (1992). SCREENING OF NEW ANTICANCER AGENTS INVITRO USING PANELS OF HUMAN CELL-LINES DERIVED FROM NONSEMINOMATOUS GERM-CELL TUMORS AND TRANSITIONAL CELL CARCINOMAS OF THE BLADDER. EUR J CANCER, 28A(10), 1617 - 1622.

    1991

    • MASTERS J (1991). Human cancer in primary culture.
    • FRY AM, CHRESTA CM, DAVIES SM, WALKER MC, HARRIS AL, HARTLEY JA, MASTERS JRW, HICKSON ID (1991). RELATIONSHIP BETWEEN TOPOISOMERASE-II LEVEL AND CHEMOSENSITIVITY IN HUMAN TUMOR-CELL LINES. CANCER RES, 51(24), 6592 - 6595.

    1990

    • MASTERS JRW, MCDERMOTT BJ, JENKINS WEA, FENWICK E, SHAH PJR, MUNDY AR, LOADMAN PM, BIBBY MC (1990). THIOTEPA PHARMACOKINETICS DURING INTRAVESICAL CHEMOTHERAPY AND THE INFLUENCE OF TWEEN-80. CANCER CHEMOTH PHARM, 25(4), 267 - 273.
    • WALKER MC, POVEY S, PARRINGTON JM, RIDDLE PN, KNUECHEL R, MASTERS JRW (1990). DEVELOPMENT AND CHARACTERIZATION OF CISPLATIN-RESISTANT HUMAN TESTICULAR AND BLADDER-TUMOR CELL-LINES. EUR J CANCER, 26(6), 742 - 747.
    • Pope AJ, Masters JRW, MacRobert AJ (1990). The Photodynamic Effect of A Pulsed Dye-Laser on Human Bladder-Carcinoma Cells-Invitro. Urological Research, 18(4), 267 - 270.
    • Parris CN, Walker MC, Masters JR, Arlett CF (1990). Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies.. Cancer Res, 50(23), 7513 - 7518.
    • PARRIS CN, MASTERS JRW, GREEN MHL (1990). PSV3NEO TRANSFECTION AND RADIOSENSITIVITY OF HUMAN CANCER CELL-LINES. CANCER LETT, 55(2), 171 - 175.

    1989

    • MATSON PL, JUNK SM, MASTERS JRW, PRYOR JP, YOVICH JL (1989). THE INCIDENCE AND INFLUENCE UPON FERTILITY OF ANTISPERM ANTIBODIES IN SEMINAL FLUID FOLLOWING VASECTOMY REVERSAL. INT J ANDROL, 12(2), 98 - 103.
    • MASTERS JRW, CAMPLEJOHN RS, PARKINSON MC, WOODHOUSE CRJ (1989). DNA PLOIDY AND THE PROGNOSIS OF STAGE PT1 BLADDER-CANCER. BRIT J UROL, 64(4), 403 - 408.
    • Knuchel R, Hofstaedter F, Jenkins WEA, Masters JRW (1989). Intravesical chemotherapy: comparison of in vitro saensitivities between monolayers and spheroids from the bladder tumor cell line MGH-U1. Cancer Research, 49, 1397 - 1401.

    1988

    • MASTERS JRW, VESEY SG, MUNN CF, EVAN GI, WATSON JV (1988). C-MYC ONCOPROTEIN LEVELS IN BLADDER-CANCER. UROL RES, 16(5), 341 - 344.
    • Walker L, Walker MC, Parris CN, Masters JR (1988). Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro.. Urol Res, 16(4), 329 - 331.
    • BEDFORD P, FICHTINGERSCHEPMAN AMJ, SHELLARD SA, WALKER MC, MASTERS JRW, HILL BT (1988). DIFFERENTIAL REPAIR OF PLATINUM-DNA ADDUCTS IN HUMAN BLADDER AND TESTICULAR-TUMOR CONTINUOUS CELL-LINES. CANCER RES, 48(11), 3019 - 3024.
    • PARRIS CN, ARLETT CF, LEHMANN AR, GREEN MHL, MASTERS JRW (1988). DIFFERENTIAL SENSITIVITIES TO GAMMA-RADIATION OF HUMAN BLADDER AND TESTICULAR-TUMOR CELL-LINES. INT J RADIAT BIOL, 53(4), 599 - 608.
    • MASTERS JRW, BEDFORD P, KEARNEY A, POVEY S, FRANKS LM (1988). BLADDER-CANCER CELL-LINE CROSS-CONTAMINATION - IDENTIFICATION USING A LOCUS-SPECIFIC MINISATELLITE PROBE. BRIT J CANCER, 57(3), 284 - 286.

    1987

    • BEDFORD P, WALKER MC, SHARMA HL, PERERA A, MCAULIFFE CA, MASTERS JRW, HILL BT (1987). FACTORS INFLUENCING THE SENSITIVITY OF 2 HUMAN BLADDER-CARCINOMA CELL-LINES TO CIS-DIAMMINEDICHLORO-PLATINUM(II). CHEM-BIOL INTERACT, 61(1), 1 - 15.
    • PARRIS CN, MASTERS JRW, WALKER MC, NEWMAN B, RIDDLE P, ENGLISH P (1987). INTRAVESICAL CHEMOTHERAPY - COMBINATION WITH TWEEN 80 INCREASES CYTOTOXICITY INVITRO. UROL RES, 15(1), 17 - 20.
    • MASTERS JRW, CAMPLEJOHN RS, MILLIS RR, RUBENS RD (1987). HISTOLOGICAL GRADE, ELASTOSIS, DNA PLOIDY AND THE RESPONSE TO CHEMOTHERAPY OF BREAST-CANCER. BRIT J CANCER, 55(4), 455 - 457.
    • WALKER MC, PARRIS CN, MASTERS JRW (1987). DIFFERENTIAL SENSITIVITIES OF HUMAN TESTICULAR AND BLADDER-TUMOR CELL-LINES TO CHEMOTHERAPEUTIC DRUGS. J NATL CANCER I, 79(2), 213 - 216.
    • HABIB NA, WOOD CB, APOSTOLOV K, BARKER W, HERSHMAN MJ, ASLAM M, HEINEMANN D, FERMOR B, WILLIAMSON RCN, JENKINS WE, MASTERS JRW, EMBLETON MJ (1987). STEARIC-ACID AND CARCINOGENESIS. BRIT J CANCER, 56(4), 455 - 458.
    • BEDFORD P, SHELLARD SA, WALKER MC, WHELAN RDH, MASTERS JRW, HILL BT (1987). DIFFERENTIAL EXPRESSION OF COLLATERAL SENSITIVITY OR RESISTANCE TO CISPLATIN IN HUMAN BLADDER-CARCINOMA CELL-LINES PREEXPOSED INVITRO TO EITHER X-IRRADIATION OR CISPLATIN. INT J CANCER, 40(5), 681 - 686.

    1986

    • MASTERS JRW, HEPBURN PJ (1986). HUMAN BLADDER-CANCER INVITRO DRUG SENSITIVITIES - RANGE AND STABILITY IN LONG-TERM CULTURE. BRIT J CANCER, 54(1), 131 - 135.
    • MASTERS JRW, MILLIS RR, RUBENS RD (1986). RESPONSE TO ENDOCRINE THERAPY AND BREAST-CANCER DIFFERENTIATION. BREAST CANCER RES TR, 7(1), 31 - 34.
    • Groos E, Walker L, Masters JRW (1986). Intravesical chemotherapy: studies on the relationship between pH and cytotoxicity. Cancer, 58, 1199 - 1203.
    • WALKER MC, MASTERS JRW, PARRIS CN, HEPBURN PJ, ENGLISH PJ (1986). INTRAVESICAL CHEMOTHERAPY - INVITRO STUDIES ON THE RELATIONSHIP BETWEEN DOSE AND CYTOTOXICITY. UROL RES, 14(3), 137 - 140.
    • MASTERS JRW, HEPBURN PJ, WALKER L, HIGHMAN WJ, TREJDOSIEWICZ LK, POVEY S, PARKAR M, HILL BT, RIDDLE PR, FRANKS LM (1986). TISSUE-CULTURE MODEL OF TRANSITIONAL CELL-CARCINOMA - CHARACTERIZATION OF 22 HUMAN UROTHELIAL CELL-LINES. CANCER RES, 46(7), 3630 - 3636.
    • GROOS E, MASTERS JRW, SOLOWAY MS (1986). INTRAVESICAL CHEMOTHERAPY - STUDIES ON THE RELATIONSHIP BETWEEN OSMOLALITY AND CYTOTOXICITY. J UROLOGY, 136(2), 399 - 402.

    1985

    • FORD TF, BUTCHER DN, SAMUELL CT, MASTERS JRW, PARKINSON MC, OLIVER RTD (1985). SERUM AND TISSUE TUMOR-MARKERS IN SEMINOMAS. BRIT J UROL, 57(6), 750 - 754.
    • HEPBURN PJ, OLIVER RTD, RILEY PA, HILL BT, MASTERS JRW (1985). COMPARISON OF THE CYTO-TOXIC ACTIVITIES OF CHEMOTHERAPEUTIC DRUGS USING A HUMAN BLADDER-CANCER CELL-LINE. UROL RES, 13(1), 27 - 34.
    • FORD TF, BUTCHER DN, MASTERS JRW, PARKINSON MC (1985). IMMUNOCYTOCHEMICAL LOCALIZATION OF PROSTATE-SPECIFIC ANTIGEN - SPECIFICITY AND APPLICATION TO CLINICAL-PRACTICE. BRIT J UROL, 57(1), 50 - 55.
    • TREJDOSIEWICZ LK, SOUTHGATE J, DONALD JA, MASTERS JRW, HEPBURN PJ, HODGES GM (1985). MONOCLONAL-ANTIBODIES TO HUMAN UROTHELIAL CELL-LINES AND HYBRIDS - PRODUCTION AND CHARACTERIZATION. J UROLOGY, 133(3), 533 - 538.
    • BUTCHER DN, GREGORY WM, GUNTER PA, MASTERS JRW, PARKINSON MC (1985). THE BIOLOGICAL AND CLINICAL-SIGNIFICANCE OF HCG-CONTAINING CELLS IN SEMINOMA. BRIT J CANCER, 51(4), 473 - 478.

    1984

    • HILL BT, BELLAMY AS, METCALFE S, HEPBURN PJ, MASTERS JRW, WHELAN RDH (1984). IDENTIFICATION OF SYNERGISTIC COMBINATIONS OF SPIROGERMANIUM WITH 5-FLUOROURACIL OR CISPLATIN USING A RANGE OF HUMAN-TUMOR CELL-LINES INVITRO. INVEST NEW DRUG, 2(1), 29 - 33.
    • SUTHERLAND PD, MATSON PL, MASTERS JRW, PRYOR JP (1984). ASSOCIATION BETWEEN INFERTILITY FOLLOWING REVERSAL OF VASECTOMY AND THE PRESENCE OF SPERM AGGLUTINATING ACTIVITY IN SEMEN. INT J ANDROL, 7(6), 503 - 508.

    1983

    • HEPBURN P, MASTERS J (1983). The biological characteristics of continuous cell lines derived from human bladder. In BRYAN G, COHEN S (Ed.), The pathology of bladder cancer, vol 2 (pp. 213 - 227). : CRC Press.
    • MASTERS JRW, PARKINSON MC, MILLER ID, HORNE CHW (1983). THE PREVALENCE AND PROGNOSTIC-SIGNIFICANCE OF TROPHOBLASTIC PROTEINS IN TESTICULAR TERATOMA. DIAGN HISTOPATHOL, 6(3-4), 247 - 252.
    • MASTERS J (1983). An overview of the role of organ culture for human tumour biopsies. In DENDY P, HILL B (Ed.), Human tumour drug sensitivity testing in vitro (pp. 163 - 177). : Academic Press.
    • METCALFE SA, WHELAN RDH, MASTERS JRW, HILL BT (1983). INVITRO RESPONSES OF HUMAN-PROSTATE TUMOR-CELL LINES TO A RANGE OF ANTI-TUMOR AGENTS. INT J CANCER, 32(3), 351 - 358.
    • SMITH C, MASTERS J, METCALFE S, GHANADIAN R (1983). ANDROGEN METABOLISM BY HUMAN PROSTATIC TUMORS IN ORGAN-CULTURE. EUR J CANCER, 19(7), 929 - 934.

    1980

    • KING R, HAYWARD J, MASTERS J, MILLIS R, RUBENS R (1980). Steroid receptor assays as prognostic aids in the treatment of breast cancer. In WITTLIFF J, DAPUNT O (Ed.), Steroid receptors and hormone-dependent neoplasia (pp. 249 - 256). : Masson Publishing Co.,.
    • MASTERS JRW, RIGBY CC, MUNSON KW, TEE DEH (1980). THE MAKARI SKIN-TEST AND IMMUNOCOMPETENCE IN BLADDER-CANCER. UROL RES, 8(2), 95 - 100.
    • BAGSHAW HA, MASTERS JRW, PRYOR JP (1980). FACTORS INFLUENCING THE OUTCOME OF VASECTOMY REVERSAL. BRIT J UROL, 52(1), 57 - 60.
    • GARDINER RA, MASTERS JRW, MOLLAND EA (1980). EXPERIMENTAL TRYPSIN-INDUCED UROTHELIAL CELL-SEPARATION INVIVO. BRIT J UROL, 52(4), 295 - 300.
    • MASTERS JRW, KRISHNASWAMY A, RIGBY CC, ODONOGHUE EPN (1980). QUANTITATIVE ORGAN-CULTURE - AN APPROACH TO PREDICTION OF TUMOR RESPONSE. BRIT J CANCER, 41, 199 - 202.

    1979

    • MASTERS JRW, MILLIS RR, KING RJB, RUBENS RD (1979). ELASTOSIS AND RESPONSE TO ENDOCRINE THERAPY IN HUMAN-BREAST CANCER. BRIT J CANCER, 39(5), 536 - 539.

    1978

    • MASTERS JRW, HAWKINS RA, SANGSTER K, HAWKINS W, SMITH II, SHIVAS AA, ROBERTS MM, FORREST APM (1978). ESTROGEN RECEPTORS, CELLULARITY, ELASTOSIS AND MENSTRUAL STATUS IN HUMAN BREAST-CANCER. EUR J CANCER, 14(3), 303 - 307.

    1977

    • MASTERS JRW, DRIFE JO, SCARISBRICK JJ (1977). CYCLIC VARIATION OF DNA-SYNTHESIS IN HUMAN BREAST EPITHELIUM. J NATL CANCER I, 58(5), 1263 - 1265.
    • MASTERS JRW, SANGSTER K, SMITH II (1977). HORMONAL SENSITIVITY OF HUMAN BREAST TUMORS INVITRO - PENTOSE-SHUNT ACTIVITY. CANCER, 39(5), 1978 - 1980.

    1976

    • MASTERS JRW (1976). EPITHELIAL-MESENCHYMAL INTERACTION DURING LUNG DEVELOPMENT - EFFECT OF MESENCHYMAL MASS. DEV BIOL, 51(1), 98 - 108.
    • MASTERS JRW, SANGSTER K, HAWKINS RA, SHIVAS AA (1976). ELASTOSIS AND ESTROGEN RECEPTORS IN HUMAN BREAST-CANCER. BRIT J CANCER, 33(3), 342 - 343.
    • MASTERS JRW, SANGSTER K, SMITH II, FORREST APM (1976). HUMAN BREAST CARCINOMATA IN ORGAN-CULTURE - EFFECT OF HORMONES. BRIT J CANCER, 33(5), 564 - 566.
    • MASTERS JRW (1976). EFFECT OF CARCINOGENS ON MITOTIC FREQUENCY IN MOUSE LUNG PRIMORDIA INVITRO. EUR J CANCER, 12(3), 219 - 225.

    • NAABY-HANSEN S, NAGANO K, GAFFNEY P, MASTERS J, CRAMER R (). Proteomics in the analysis of prostate cancer. In RUSSELL P, JACKSON P, KINGSLEY E (Ed.), Methods in molecular medicine 81: Prostate cancer methods and protocols (pp. 277 - 297). : Humana Press Inc..
    • AHMED A, BISSON I, FOLEY C, MASTERS J (). Stem cells in the prostate. In KIRBY R, PARTIN A, FENELEY M, PARSONS J (Ed.), Prostate cancer: principles and practice (pp. - ). : .
    • WHITE S, MASTERS J, WOOLF A (). Culture of renal and bladder epithelial cells. In HARRIS A (Ed.), Practical animal cell biology series: epithelial cells (pp. - ). : Cambridge University Press.